Newsletter

[vc_row us_bg_image=”3115″ us_bg_size=”contain” us_bg_repeat=”no-repeat” el_class=”masthead-newsletter” us_bg_image_source=”media”][vc_row el_class=”newsletter-row”] THE MISCH INSTITUTE NEWSLETTER [vc_row color_scheme=”alternate” el_class=”newsletter-content”][vc_column width=”1/2″ el_class=”orange-right”] New Prophylactic Antibiotic Protocol for Sinus Graft Procedures [us_image image=”3123″ align=”center”]For years, Augmentin (Amoxicillin-clavulanate) has been used as the first line antibiotic for the therapeutic and prophylactic treatment of sinus graft procedures because of its superior beta-lactamase coverage. With […]

[vc_row us_bg_image=”3115″ us_bg_size=”contain” us_bg_repeat=”no-repeat” el_class=”masthead-newsletter” us_bg_image_source=”media”][vc_row el_class=”newsletter-row”] THE MISCH INSTITUTE NEWSLETTER [vc_row color_scheme=”alternate” el_class=”newsletter-content”][vc_column width=”1/2″ el_class=”orange-right”] Beware of the Complications of a New Drug Class: The “Biologics” A new class of therapeutic drugs are becoming more popular in the treatment of an array of medical conditions such as autoimmune disease and cancers. These new drugs […]